Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial
雷珠单抗生物类似药SB11（Byooviz）与参考产品Lucentis的免疫原性及其与疗效、安全性和药代动力学的关联：一项3期随机临床试验的事后分析
期刊:Jama Ophthalmology
影响因子:9.2
doi:10.1001/jamaophthalmol.2022.5403
Bressler, Neil M; Kim, Taehyung; Oh, Inkyung; Russo, Paola; Kim, Mercy Yeeun; Woo, Se Joon
